BioAtla, Inc. - BCAB STOCK NEWS

BioAtla, Inc. (BCAB) reported significant progress in its clinical trials, with top-line interim data from the Phase 2 study of Mecbotamab vedotin (BA3011) in sarcoma showing promising results. Partial responses were noted in 33% of undifferentiated pleomorphic sarcoma patients, while the progression-free survival (PFS) rate reached 67% in osteosarcoma patients. The company ended Q1 2022 with a cash balance of $219.4 million, expected to fund operations into mid-2024. First quarter net loss was $24.3 million, an increase from $18.7 million in Q1 2021.

BioAtla, Inc. (Nasdaq: BCAB) announced a conference call on May 4, 2022, at 4:30 p.m. ET to discuss Q1 2022 financial results and provide topline data from the Phase 2 study of mecbotamab vedotin (BA3011) in sarcoma. The call will include updates on ongoing clinical programs like BA3011, ozuriftamab vedotin (BA3021), and CAB-CTLA-4 (BA3071). The press release with financial results will be available before the call on the company’s website.

BioAtla, Inc. (Nasdaq: BCAB) reported its Q4 and full-year 2021 financial results, revealing a net loss of $95.4 million, up from $35.9 million in 2020. R&D expenses surged to $58.3 million, reflecting ongoing clinical trials and development activities. The company maintains a strong cash position with $245 million, expected to fund operations through mid-2024. BioAtla is advancing its lead candidates, mecbotamab vedotin and ozuriftamab vedotin, into Phase 2 clinical trials, with interim updates anticipated in 2022. The company also plans to file INDs for several innovative product candidates.

BioAtla (Nasdaq: BCAB) announced a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to explore its lead candidates, BA3011 and BA3021, in combination with Opdivo (nivolumab) for solid tumors. BioAtla will sponsor the trials and bear execution costs, while Bristol Myers Squibb will supply Opdivo. Both candidates target AXL and ROR2, which are significant in various cancers, especially after prior anti-PD-1 therapy. This collaboration aims to enhance treatment options for patients with unmet medical needs.

BioAtla has appointed Edward L. Williams to its Board of Directors, enhancing its leadership as it progresses to late-stage clinical trials. Williams brings extensive experience from his tenure at Novo Nordisk, where he tripled biopharmaceutical revenues and held various executive roles. His expertise will contribute significantly to BioAtla's commercialization strategies for its proprietary Conditionally Active Biologics (CAB) antibody therapeutics. The company's key programs, mecbotamab vedotin and ozuriftamab vedotin, are currently in Phase 2 trials in the U.S.

BioAtla (Nasdaq: BCAB) reported its Q3 2021 financial results, showcasing a net loss of $22.9 million, up from $11.6 million in Q3 2020. Cash reserves stand at $269.9 million, sufficient for operations into H1 2024. The company is advancing Phase 2 trials for its lead candidates, BA3011 and BA3021, and anticipates interim data for BA3011 by year-end. Hiring of Sheri Lydick as Senior VP of Commercial Strategy aims to enhance product launch capabilities. R&D expenses surged to $16.6 million, reflecting increased investment in its pipeline.

BioAtla has announced a private placement to issue 2.7 million shares of common stock at $28 per share, raising $75 million in gross proceeds. The funds will primarily support clinical development, medical affairs, and general corporate purposes. Institutional investors participating include Great Point Partners and Deerfield Management Company. The placement is expected to close on September 30, 2021, subject to customary conditions. The shares are unregistered and will not be sold in the U.S. without proper registration.

BioAtla, Inc. (Nasdaq: BCAB) reported second-quarter financial results for 2021, showing a net loss of $30.4 million, compared to $6.2 million in Q2 2020. The company is advancing Phase 2 trials for two lead products, BA3011 and BA3021, targeting challenging cancer types. Cash and cash equivalents stood at $207.6 million, expected to fund operations through 2023. Notably, R&D expenses surged to $14.9 million from $2.9 million in the previous year, reflecting increased investment in product development.

BioAtla, Inc. (Nasdaq: BCAB) reports significant advancements in Q1 2021, focusing on Phase 2 trials for CAB-AXL-ADC and CAB-ROR2-ADC. Cash reserves stand at $221.2 million, adequate to fund operations into 2023. R&D expenses surged to $10.4 million, reflecting an investment in clinical programs. The net loss was $18.7 million, up from $1.6 million YoY. The company is optimistic, with trials showing promise in advanced solid tumors. Upcoming data readouts are expected by year-end, indicating strong potential for future growth.